Shares of Pluri Inc. (NASDAQ:PLUR – Get Rating) were up 4.7% during trading on Thursday . The company traded as high as $0.92 and last traded at $0.91. Approximately 111,089 shares were traded during trading, a decline of 76% from the average daily volume of 457,724 shares. The stock had previously closed at $0.87.
Pluri Trading Up 2.2 %
The company has a current ratio of 9.91, a quick ratio of 9.91 and a debt-to-equity ratio of 0.77. The business's fifty day moving average is $0.77.
Get
Pluri alerts:
Institutional Trading of Pluri
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PLUR. Renaissance Technologies LLC purchased a new stake in Pluri during the third quarter valued at approximately $81,000. Green Alpha Advisors LLC purchased a new stake in shares of Pluri in the third quarter worth $44,000. Values First Advisors Inc. purchased a new stake in shares of Pluri in the third quarter worth $38,000. Finally, Jane Street Group LLC purchased a new stake in shares of Pluri in the third quarter worth $28,000. 8.75% of the stock is owned by hedge funds and other institutional investors.
About Pluri
(Get Rating)
Pluri Inc, a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the muscle recovery following surgery for hip fracture; and Phase I/II clinical trial for the treatment of steroid-refractory graft versus host disease in collaboration with Tel Aviv Sourasky Medical Center, as well as completed a Phase II clinical trial for the treatment of acute respiratory distress syndrome associated with COVID-19 and a Phase I clinical trial for incomplete recovery following bone marrow transplantation.
Featured Stories
- Get a free copy of the StockNews.com research report on Pluri (PLUR)
- MarketBeat: Week in Review 12/05 – 12/09
- There Is Fundamental Value In Broadcom, And It Yields 3.35%
- Costco vs Amazon: an end of the year showdown
- Discount Retailers Could Make Good Bargain Stocks
- Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
木曜日の取引では、Pluri Inc.(ナスダックコード:PLUR-GET)の株価が4.7%上昇した。同社の株価は一時0.92ドルに達し、最新は0.91ドルだった。当日の出来高は約111,089株で、457,724株の1日平均出来高より76%低下した。この株のこれまでの終値は0.87ドルだった。
Pluri株価は2.2%上昇
同社の流動比率は9.91、速動比率は9.91、債務権益比率は0.77。この業務の50日移動平均線入位は0.77ドルであった
それを手に入れて
プルリ警報:
プルリの機関取引
一部のヘッジファンドや他の機関投資家は最近PLURの株式を増資または減少させた。復興技術有限責任会社は第3四半期にPluriの新株式を購入し、約81,000ドルの価値がある。Green Alpha Advisors LLCは第3四半期に44,000ドルのPluri新株を購入した。Values First Advisors Inc.は第3四半期に3.8万ドルのPluri新株を購入した。最後に、簡街グループは第3四半期に2.8万ドルのPluri新株を購入した。8.75%の株式はヘッジファンドと他の機関投資家が保有している
Pluriについて
(格付けを取得する)
Pluri Inc.はバイオテクノロジー会社であり,胎盤に基づく細胞治療製品の開発に専念し,炎症,筋損傷,血液疾患の治療に用いられている。同社は寛骨骨折術後筋回復に対するPLX−PADの第3段階臨床試験,テルアビブSourasky医学センターと協力してホルモン難治性移植片対宿主疾患を治療するI/II段階臨床試験,および新冠肺炎に関連する急性呼吸窮迫症候群を治療する第2段階臨床試験と骨髄移植後不完全回復の第1段階臨床試験を含む胎盤拡大(PLX)に基づく細胞治療製品を開発した。
特集記事
- StockNews.com Pluriに関する研究報告(PLUR)を無料で取得
- MarketBeat:1週間を振り返る12/05-12/09
- ボートンにはファンダメンタルバリューがあり、収益率は3.35%です
- 好市多VSアマゾン:年末屋台
- 割引小売業者は安物を作ることができます
- ファイザー、ジョンソンはこの指数に勝ち続けることができますか?
Pluri Dailyのニュースと格付けを受けます-MarketBeat.comの無料毎日電子メール時事通信を介して、Pluriおよび関連会社の最新のニュースおよびアナリスト格付けの毎日の簡単な要約を受信するために、以下に電子メールアドレスを入力します。